Ignite Creation Date:
2024-05-05 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00515762
Status:
COMPLETED
Last Update Posted:
2011-08-09
First Post:
2007-08-13
Brief Title:
Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling
Sponsor:
Hospital San Carlos Madrid
Organization:
Hospital San Carlos Madrid
Study Overview
Official Title:
Pilot Trial of Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling ELASTO-GEL CAPSin Breast Cancer Patients
Status:
COMPLETED
Status Verified Date:
2010-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Persistent alopecia following adjuvant docetaxel for breast cancer is a side-effect that has been recently described This pilot trial explores the capacity of a cooling cap Elasto-gel to prevent persistent alopecia in breast cancer patients treated with adjuvant docetaxel regimens
Detailed Description:
Persistent alopecia following adjuvant docetaxel for breast cancer is a side-effect that has been recently described Docetaxel is toxic to skin and skin annexes and can produce nail toxicity and persistent alopecia Nail toxicity has been successfully prevented by means of hypothermic gloves and slippers Elasto-gel Southwest Technologies Inc North Kansas City MO This pilot trial explores the capacity of a cooling cap Elasto-gel to prevent persistent alopecia in breast cancer patients treated with adjuvant docetaxel regimens
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None